新着情報

Featured

Lotus Pharmaceutical, EF Biotech, and Hualian Tzu Chi Hospital to Form Alliance in Conducting Clinical Trial For New Treatments For Brain Cancer

Lotus Pharmaceutical, Hualian Tzu Chi Hospital and EF Biotech signed MOU today regarding the co-development of the combo targeted therapy of Cerebraca wafer and Temozolomide for the treatment of Glioblastoma Multiformis (GBM). Under the agreement, clinical trial of this new treatment for brain cancer will begin in June. Superintendent of Tzu Chi Shinn-Zong Lin, Chairman of EF Biotech Doctor Pei-Wen Chou, and Sales Director of Lotus Pharmaceutical Dino Kuan appeared at the signing press conference today at 2pm.

Read More
マネジメントチーム

確固たる実績と高い利益をもたらした、経験豊富なマネジメントチーム。

ニュース・アラート

ニュース・アラートを見るためには、Emailを入力し登録が必要です。